{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T01:04:39Z","timestamp":1775178279075,"version":"3.50.1"},"reference-count":41,"publisher":"Georg Thieme Verlag KG","issue":"04","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int J Angiol"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Cardiovascular (CV) disease is the leading cause of premature death in ankylosing spondylitis (AS). Atherosclerosis and AS share similar pathogenic mechanisms. The proven benefits of angiotensin-receptor blockers (ARBs) in atherosclerotic cardiovascular disease and their role in immune mediation provide strong rationale to investigate its impact with olmesartan on inflammation and endothelial dysfunction in AS. To investigate the effect of olmesartan on inflammation and endothelial dysfunction in AS. 40 AS patients were randomized to receive 24 weeks of treatment with olmesartan (10\u2009mg\/day, n\u2009=\u200920) and placebo (n\u2009=\u200920) as an adjunct to existing stable antirheumatic drugs. Markers of endothelial function included the following: flow-mediated dilation (FMD) assessed by AngioDefender, endothelial progenitor cells (EPCs) estimated by flow cytometry, nitrite (nitric oxide surrogate), intracellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1) and inflammatory measures including Bath ankylosing spondylitis disease activity index (BASDAI), ankylosing spondylitis disease activity score (ASDAS) and bath ankylosing spondylitis functional index (BASFI); erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP); proinflammatory cytokines (interleukin-1 [IL-1], IL-6, tumor necrosis factor-\u03b1 [TNF-\u03b1]) and marker of oxidative stress\u2013 thiobarbituric acid reactive substances (TBARS) estimated at baseline and after treatment. Health assessment questionnaire disability index (HAQDI), 36-item short form survey (SF-36), and systematic coronary risk evaluation (SCORE) were estimated using standard tools. FMD improved significantly in the olmesartan group (5.83\u2009\u00b1\u20090.31% to 7.68\u2009\u00b1\u20090.27%, p \u2009\u2264\u2009 0.05) as compared with placebo (5.89\u2009\u00b1\u20090.35% to 6.04\u2009\u00b1\u20090.32%, p\u2009=\u20090.33). EPC population, nitrite, VCAM-1, and TBARS levels improved significantly in olmesartan group as compared with placebo (p \u2264 0.05). Olmesartan significantly decreased ASDAS, BASDAI, BASFI, ESR, CRP, IL-6, TNF-\u03b1, and SCORE as compared with placebo. HAQDI and SF-36 (PH) scores improved significantly in olmesartan group as compared with placebo. Olmesartan reduces inflammatory disease activity, improves quality of life (QOL), and decreases CV risk demonstrating the immunomodulatory, vasculoprotective, and cardioprotective potential of this drug in AS.<\/jats:p>","DOI":"10.1055\/s-0040-1722738","type":"journal-article","created":{"date-parts":[[2021,1,29]],"date-time":"2021-01-29T23:53:00Z","timestamp":1611964380000},"page":"262-270","source":"Crossref","is-referenced-by-count":7,"title":["Angiotensin-Receptor Blockade Improves Inflammation and Endothelial Dysfunction in Ankylosing Spondylitis: ARB-AS Study"],"prefix":"10.1055","volume":"30","author":[{"given":"Nidhi","family":"Garg","sequence":"additional","affiliation":[{"name":"Chitkara College of Pharmacy, Chitkara University, Punjab, India"},{"name":"Department of Pharmaceutical Sciences & Drug Research, Punjabi University, Patiala, Punjab, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pawan","family":"Krishan","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences & Drug Research, Punjabi University, Patiala, Punjab, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashit","family":"Syngle","sequence":"additional","affiliation":[{"name":"Cardio Rheuma & Healing Touch City Clinic, Chandigarh & Rheumatologist- Fortis Multi Speciality Hospital, Mohali, India"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2021,1,29]]},"reference":[{"issue":"01","key":"ref1","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1177\/1759720X12468658","article-title":"Axial spondyloarthritis: is there a treatment of choice?","volume":"5","author":"D Poddubnyy","year":"2013","journal-title":"Ther Adv Musculoskelet Dis"},{"issue":"03","key":"ref2","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.semarthrit.2004.07.010","article-title":"Cardiovascular risk profile of patients with spondylarthropathies, particularly ankylosing spondylitis and psoriatic arthritis","volume":"34","author":"M J Peters","year":"2004","journal-title":"Semin Arthritis Rheum"},{"issue":"06","key":"ref3","doi-asserted-by":"crossref","first-page":"409","DOI":"10.7326\/M14-2470","article-title":"Patients with ankylosing spondylitis have increased cardiovascular and cerebrovascular mortality: a population-based study","volume":"163","author":"N N Haroon","year":"2015","journal-title":"Ann Intern Med"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.jaut.2007.02.004","article-title":"The pathogenesis of atherosclerosis in autoimmune rheumatic diseases: roles of inflammation and dyslipidemia","volume":"28","author":"B H Hahn","year":"2007","journal-title":"J Autoimmun"},{"key":"ref5","first-page":"S124","article-title":"Comparison of cardiovascular risk in ankylosing spondylitis and rheumatoid arthritis","volume":"27","author":"D McCarey","year":"2009","journal-title":"Clin Exp Rheumatol"},{"issue":"07","key":"ref6","doi-asserted-by":"crossref","first-page":"11324","DOI":"10.3390\/ijms150711324","article-title":"Endothelial dysfunction in chronic inflammatory diseases","volume":"15","author":"C M Steyers III","year":"2014","journal-title":"Int J Mol Sci"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/S0140-6736(07)60242-6","article-title":"Renin-angiotensin system and cardiovascular risk","volume":"369","author":"R E Schmieder","year":"2007","journal-title":"Lancet"},{"issue":"01","key":"ref8","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.atherosclerosis.2010.05.020","article-title":"Angiotensin II induces C-reactive protein expression through ERK1\/2 and JNK signaling in human aortic endothelial cells","volume":"212","author":"C Han","year":"2010","journal-title":"Atherosclerosis"},{"issue":"03","key":"ref9","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1136\/ard.2007.086777","article-title":"Microvascular function is impaired in ankylosing spondylitis and improves after tumour necrosis factor \u03b1 blockade","volume":"68","author":"I C van Eijk","year":"2009","journal-title":"Ann Rheum Dis"},{"issue":"07","key":"ref10","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1007\/s10067-010-1402-x","article-title":"Endothelial dysfunction in ankylosing spondylitis improves after tumor necrosis factor-\u03b1 blockade","volume":"29","author":"A Syngle","year":"2010","journal-title":"Clin Rheumatol"},{"issue":"07","key":"ref11","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1007\/s10067-013-2233-3","article-title":"Spironolactone improves endothelial dysfunction in ankylosing spondylitis","volume":"32","author":"A Syngle","year":"2013","journal-title":"Clin Rheumatol"},{"issue":"03","key":"ref12","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1161\/01.CIR.0000153272.48711.B9","article-title":"Irbesartan and lipoic acid improve endothelial function and reduce markers of inflammation in the metabolic syndrome: results of the Irbesartan and Lipoic Acid in Endothelial Dysfunction (ISLAND) study","volume":"111","author":"S Sola","year":"2005","journal-title":"Circulation"},{"issue":"09","key":"ref13","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1161\/01.CIR.0000140265.21608.8E","article-title":"Antiinflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammation","volume":"110","author":"D Fliser","year":"2004","journal-title":"Circulation"},{"issue":"04","key":"ref14","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/art.1780270401","article-title":"Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria","volume":"27","author":"S van der Linden","year":"1984","journal-title":"Arthritis Rheum"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"971453","DOI":"10.1155\/2015\/971453","article-title":"Emerging risk biomarkers in cardiovascular diseases and disorders","volume":"2015","author":"R K Upadhyay","year":"2015","journal-title":"J Lipids"},{"issue":"06","key":"ref16","first-page":"853","article-title":"Endothelial dysfunction in diabetes mellitus","volume":"3","author":"H AR Hadi","year":"2007","journal-title":"Vasc Health Risk Manag"},{"issue":"06","key":"ref17","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1007\/s10067-015-2912-3","article-title":"Rosuvastatin improves endothelial dysfunction in ankylosing spondylitis","volume":"34","author":"N Garg","year":"2015","journal-title":"Clin Rheumatol"},{"issue":"01","key":"ref18","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1055\/s-0036-1593445","article-title":"Endothelial progenitor cells as a marker of endothelial dysfunction and atherosclerosis in ankylosing spondylitis: a cross-sectional study","volume":"26","author":"I Verma","year":"2017","journal-title":"Int J Angiol"},{"issue":"01","key":"ref19","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1006\/abio.2002.5676","article-title":"Spectrophotometric determination of serum nitrite and nitrate by copper-cadmium alloy","volume":"306","author":"K V Sastry","year":"2002","journal-title":"Anal Biochem"},{"issue":"02","key":"ref20","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/0003-2697(79)90738-3","article-title":"Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction","volume":"95","author":"H Ohkawa","year":"1979","journal-title":"Anal Biochem"},{"key":"ref21","first-page":"43","article-title":"Rheumatology: made in India (Camps, COPCORD, HLA, Ayurveda, HAQ, WOMAC and drug trials)","volume":"12","author":"A Chopra","year":"2004","journal-title":"Journal of Indian Rheumatology Association"},{"issue":"24","key":"ref22","doi-asserted-by":"crossref","first-page":"3130","DOI":"10.1097\/00007632-200012150-00008","article-title":"SF-36 health survey update","volume":"25","author":"J E Ware Jr","year":"2000","journal-title":"Spine"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-209775","article-title":"EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015\/2016 update","author":"R Agca","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"ref24","first-page":"S11","article-title":"Ankylosing spondylitis--cardiac manifestations","volume":"20","author":"D Lautermann","year":"2002","journal-title":"Clin Exp Rheumatol"},{"issue":"03","key":"ref25","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1093\/rheumatology\/kei145","article-title":"Impaired endothelial function in patients with ankylosing spondylitis","volume":"45","author":"I Sari","year":"2006","journal-title":"Rheumatology (Oxford)"},{"issue":"06","key":"ref26","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1007\/s10554-010-9616-1","article-title":"Prediction of future cardiovascular outcomes by flow-mediated vasodilatation of brachial artery: a meta-analysis","volume":"26","author":"Y Inaba","year":"2010","journal-title":"Int J Cardiovasc Imaging"},{"issue":"12","key":"ref27","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1016\/j.jacc.2007.06.013","article-title":"Olmesartan, but not amlodipine, improves endothelium-dependent coronary dilation in hypertensive patients","volume":"50","author":"M Naya","year":"2007","journal-title":"J Am Coll Cardiol"},{"issue":"06","key":"ref28","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1038\/hr.2011.11","article-title":"Olmesartan improves endothelial function in hypertensive patients: link with extracellular superoxide dismutase","volume":"34","author":"S Takiguchi","year":"2011","journal-title":"Hypertens Res"},{"issue":"05","key":"ref29","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/BF03401781","article-title":"Inducible nitric oxide synthase and inflammatory diseases","volume":"6","author":"R Zamora","year":"2000","journal-title":"Mol Med"},{"issue":"02","key":"ref30","doi-asserted-by":"crossref","first-page":"133","DOI":"10.2174\/1568016053544363","article-title":"Angiotensin II type I receptor blocker and endothelial function in humans: role of nitric oxide and oxidative stress","volume":"3","author":"Y Higashi","year":"2005","journal-title":"Curr Med Chem Cardiovasc Hematol Agents"},{"issue":"06","key":"ref31","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1016\/S0735-1097(01)01615-1","article-title":"Irbesartan, an angiotensin type 1 receptor inhibitor, regulates the vascular oxidative state in patients with coronary artery disease","volume":"38","author":"B V Khan","year":"2001","journal-title":"J Am Coll Cardiol"},{"issue":"01","key":"ref32","first-page":"OA3","article-title":"Endothelial dysfunction in ankylosing spondylitis associated with reduced endothelial progenitor cell population","volume":"3","author":"I Verma","year":"2015","journal-title":"IJRCI"},{"issue":"04","key":"ref33","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1161\/01.HYP.0000159191.98140.89","article-title":"Stimulation of endothelial progenitor cells: a new putative therapeutic effect of angiotensin II receptor antagonists","volume":"45","author":"F H Bahlmann","year":"2005","journal-title":"Hypertension"},{"issue":"04","key":"ref34","doi-asserted-by":"crossref","first-page":"275","DOI":"10.2174\/157340308786349435","article-title":"Endothelial progenitor cells dysfunction and senescence: contribution to oxidative stress","volume":"4","author":"T Imanishi","year":"2008","journal-title":"Curr Cardiol Rev"},{"issue":"02","key":"ref35","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1042\/CS20040326","article-title":"Cardiovascular risk parameters in men with ankylosing spondylitis in comparison with non-inflammatory control subjects: relevance of systemic inflammation","volume":"109","author":"H Divecha","year":"2005","journal-title":"Clin Sci (Lond)"},{"issue":"11","key":"ref36","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1136\/ard.2007.082917","article-title":"Angiotensin receptor blockers reduce erythrocyte sedimentation rate levels in patients with rheumatoid arthritis","volume":"67","author":"M E Perry","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ehj.2014.11.005","article-title":"C-reactive protein, inflammation and coronary heart disease","volume":"67","author":"A K Shrivastava","year":"2015","journal-title":"Egypt Heart J"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"754","DOI":"10.3389\/fimmu.2018.00754","article-title":"Role of C-reactive protein at sites of inflammation and infection","volume":"9","author":"N R Sproston","year":"2018","journal-title":"Front Immunol"},{"issue":"08","key":"ref39","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1002\/art.21204","article-title":"Baseline levels of C-reactive protein and prediction of death from cardiovascular disease in patients with inflammatory polyarthritis: a ten-year followup study of a primary care-based inception cohort","volume":"52","author":"N J Goodson","year":"2005","journal-title":"Arthritis Rheum"},{"issue":"11","key":"ref40","doi-asserted-by":"crossref","first-page":"3294","DOI":"10.1002\/art.30581","article-title":"Increased risk of cardiovascular and cerebrovascular diseases in individuals with ankylosing spondylitis: a population-based study","volume":"63","author":"S M Szabo","year":"2011","journal-title":"Arthritis Rheum"},{"issue":"08","key":"ref41","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1007\/s10067-008-0845-9","article-title":"Factors influencing health status and disability of patients with ankylosing spondylitis in the Czech Republic","volume":"27","author":"S Forejtov\u00e1","year":"2008","journal-title":"Clin Rheumatol"}],"container-title":["International Journal of Angiology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/s-0040-1722738.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,22]],"date-time":"2021-11-22T23:31:44Z","timestamp":1637623904000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/s-0040-1722738"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,29]]},"references-count":41,"journal-issue":{"issue":"04","published-online":{"date-parts":[[2021,11,22]]},"published-print":{"date-parts":[[2021,12]]}},"URL":"https:\/\/doi.org\/10.1055\/s-0040-1722738","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["1061-1711","1615-5939"],"issn-type":[{"value":"1061-1711","type":"print"},{"value":"1615-5939","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,29]]}}}